ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 73 filers reported holding ARBUTUS BIOPHARMA CORP in Q1 2019. The put-call ratio across all filers is 0.05 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $4,934,000 | +82.3% | 1,774,915 | 0.0% | 0.03% | +63.2% |
| Q3 2019 | $2,707,000 | -26.7% | 1,774,915 | 0.0% | 0.02% | -29.6% |
| Q2 2019 | $3,692,000 | -41.6% | 1,774,915 | +0.5% | 0.03% | -43.8% |
| Q1 2019 | $6,320,000 | -6.5% | 1,765,415 | 0.0% | 0.05% | -21.3% |
| Q4 2018 | $6,761,000 | -60.4% | 1,765,415 | 0.0% | 0.06% | -57.3% |
| Q3 2018 | $17,054,000 | +93.2% | 1,765,415 | +0.0% | 0.14% | +74.4% |
| Q2 2018 | $8,827,000 | 0.0% | 1,765,315 | 0.0% | 0.08% | 0.0% |
| Q1 2018 | $8,827,000 | -1.0% | 1,765,315 | 0.0% | 0.08% | -3.5% |
| Q4 2017 | $8,915,000 | -33.2% | 1,765,315 | -0.2% | 0.08% | -41.4% |
| Q3 2017 | $13,349,000 | -30.0% | 1,768,891 | -66.6% | 0.14% | -35.3% |
| Q2 2017 | $19,062,000 | +10.8% | 5,294,945 | 0.0% | 0.22% | +2.8% |
| Q1 2017 | $17,209,000 | +32.7% | 5,294,945 | 0.0% | 0.22% | +21.1% |
| Q4 2016 | $12,972,000 | +648500.0% | 5,294,945 | +1058889.0% | 0.18% | – |
| Q3 2016 | $2,000 | – | 500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 3,705,128 | $10,300,000 | 4.44% |
| RTW INVESTMENTS, LP | 5,666,754 | $15,754,000 | 0.59% |
| COWEN AND COMPANY, LLC | 926,200 | $2,575,000 | 0.22% |
| Hudson Bay Capital Management LP | 850,000 | $2,363,000 | 0.05% |
| LADENBURG THALMANN FINANCIAL SERVICES INC. | 1,774,915 | $4,934,000 | 0.03% |
| Point72 Asset Management, L.P. | 1,897,284 | $5,274,000 | 0.03% |
| 683 Capital Management, LLC | 77,368 | $215,000 | 0.02% |
| Secure Asset Management, LLC | 10,000 | $28,000 | 0.02% |
| Qube Research & Technologies Ltd | 166,138 | $462,000 | 0.01% |
| Verition Fund Management LLC | 174,455 | $485,000 | 0.01% |